I-MAT : A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Skin<br/>CancersCancer LocationSkin
Cancers

Systemic therapy,Treatment | SkinMerkel cell

Trial Overview Read MoreRead more

This phase II trial is evaluating how effective and well tolerated an an adjuvant immunotherapy is in patients with stage I-III Merkel Cell Carcinoma.
 

This trial is treating patients with Merkel Cell Carcinoma.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma

Other Non-Commercial Sponsor

Melanoma and Skin Cancer Trials Limited

Summary

Eligible patients will be randomised to receive 6 months of Avelumab at a dose of 800mg or a placebo as a 60-minute intravenous infusion once every 2 weeks (13 doses)

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Medical Oncology
Prahran
Ms Eleanor Edwards
El.Edwards@alfred.org.au
03 9076 2297

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next